A Phase 3 study of ULTOMIRIS (Ravulizumab) in the patients with Complement Mediated Thrombotic Microangiopathy (CM-TMA)
Latest Information Update: 23 Mar 2022
At a glance
- Drugs Ravulizumab (Primary)
- Indications Thrombotic microangiopathy
- Focus Therapeutic Use
Most Recent Events
- 30 Apr 2021 According to an Alexion Pharmaceuticals media release, the company plans to initiate this study in the second quarter of 2021.
- 30 Jul 2020 According to an Alexion Pharmaceuticals media release, the company plans to initiate this study in the first half of 2021, pending regulatory feedback.
- 03 Feb 2020 New trial record